Rare Complication of Acute Adrenocortical Dysfunction in Adrenocortical Carcinoma After Transcatheter Arterial Chemoembolization: A Case Report

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2021 Oct 8

PMID 34621849

Citations 1

Authors

Zhi-Long Wang

Xin Sun

Feng-Li Zhang

Ting Wang

Ping Li

Affiliations

Soon will be listed here.

Abstract

Background: Adrenocortical carcinoma (ACC) is a rare and highly invasive endocrine malignant tumor with a poor prognosis. Although surgical resection is the main treatment for ACC, postoperative recurrence and metastasis have become the important factors of death. Transcatheter arterial chemoembolization (TACE) is an important option for the treatment of advanced ACC with liver metastasis. However, due to the small number of patients treated for ACC, the safety of the operation is not completely clear and needs to be further studied.

Case Summary: A 47-year-old patient with ACC after surgery was admitted for reexamination by abdominal computerized tomography suggesting liver metastasis. Because the patient expressed reluctance to undergo surgery again, we treated her with TACE for the liver lesions. After treatment, symptoms of acute adrenal dysfunction such as decreased blood pressure, anorexia, and fatigue appeared, which were relieved after hydrocortisone treatment. To date, the patient's liver lesion is well controlled and no other metastases are observed.

Conclusion: We report a rare case of acute adrenal hypofunction after TACE. Glucocorticoid supplementation can alleviate the symptoms.

Citing Articles

Thiram, an inhibitor of 11ß-hydroxysteroid dehydrogenase type 2, enhances the inhibitory effects of hydrocortisone in the treatment of osteosarcoma through Wnt/β-catenin pathway.

Zhang Y, Li N, Li H, Chen M, Jiang W, Guo W BMC Pharmacol Toxicol. 2023; 24(1):20.

PMID: 36978114 PMC: 10045229. DOI: 10.1186/s40360-023-00655-0.

References

Datrice N, Langan R, Ripley R, Kemp C, Steinberg S, Wood B . Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2011; 105(7):709-13. PMC: 4136651. DOI: 10.1002/jso.23015. View

Cazejust J, De Baere T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M . Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol. 2010; 21(10):1527-32. DOI: 10.1016/j.jvir.2010.05.020. View

Fay A, Elfiky A, Telo G, McKay R, Kaymakcalan M, Nguyen P . Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014; 92(2):123-32. PMC: 4578298. DOI: 10.1016/j.critrevonc.2014.05.009. View

Megerle F, Herrmann W, Schloetelburg W, Ronchi C, Pulzer A, Quinkler M . Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2018; 103(4):1686-1695. DOI: 10.1210/jc.2017-02591. View

Else T, Kim A, Sabolch A, Raymond V, Kandathil A, Caoili E . Adrenocortical carcinoma. Endocr Rev. 2014; 35(2):282-326. PMC: 3963263. DOI: 10.1210/er.2013-1029. View

Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M . Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010; 17(2):445-53. DOI: 10.1677/ERC-09-0281. View

Libe R, Borget I, Ronchi C, Zaggia B, Kroiss M, Kerkhofs T . Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015; 26(10):2119-25. DOI: 10.1093/annonc/mdv329. View

Wong E, Jacques S, Bennett M, Gorolay V, Lee A, Clarke S . Complete response in a patient with stage IV adrenocortical carcinoma treated with adjuvant trans-catheter arterial chemo-embolization (TACE). Asia Pac J Clin Oncol. 2017; 14(3):279-281. DOI: 10.1111/ajco.12759. View

Takata M, Kebebew E, Clark O, Duh Q . Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases. Surg Endosc. 2007; 22(1):202-7. DOI: 10.1007/s00464-007-9478-3. View

10.

Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger R . European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018; 179(4):G1-G46. DOI: 10.1530/EJE-18-0608. View

11.

Erickson L, Rivera M, Zhang J . Adrenocortical carcinoma: review and update. Adv Anat Pathol. 2014; 21(3):151-9. DOI: 10.1097/PAP.0000000000000019. View

12.

Kou K, Zhang H, Zhang C, Xie E, Chen Y, Wang G . A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation. World J Surg Oncol. 2018; 16(1):43. PMC: 5836435. DOI: 10.1186/s12957-018-1326-5. View

13.

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A . Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366(23):2189-97. DOI: 10.1056/NEJMoa1200966. View

14.

Cawood T, Hunt P, OShea D, Cole D, Soule S . Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009; 161(4):513-27. DOI: 10.1530/EJE-09-0234. View

15.

Ripley R, Kemp C, Davis J, Langan R, Royal R, Libutti S . Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011; 18(7):1972-9. PMC: 3272672. DOI: 10.1245/s10434-011-1564-z. View